Divalproex Sodium NDC 68788-4100

NDC codes

FDA NDC Directory

Product NDC (as listed)68788-4100Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68788-4100Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
68788-4100-3	68788410003	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (68788-4100-3)Marketed from Apr 20, 2026
68788-4100-6	68788410006	60 TABLET, EXTENDED RELEASE in 1 BOTTLE (68788-4100-6)Marketed from Apr 20, 2026
68788-4100-9	68788410009	90 TABLET, EXTENDED RELEASE in 1 BOTTLE (68788-4100-9)Marketed from Apr 20, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Divalproex Sodium
Generic name (nonproprietary): divalproex sodium
Active ingredients: Divalproex sodium — 500 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Preferred Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 090070
Marketing start: Apr 20, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 68788-4100_dc9e4871-fb3d-4c59-81e5-2ab6e8be9b7cSPL ID dc9e4871-fb3d-4c59-81e5-2ab6e8be9b7cSPL set ID dc9e4871-fb3d-4c59-81e5-2ab6e8be9b7cRxCUI 1099569UNII 644VL95AO6
Pharmacologic class: Anti-epileptic Agent; Mood Stabilizer

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468788410003 followed by a unit qualifier and the quantity

Package 68788-4100-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 20, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Divalproex sodium extended-release tablet is indicated for: • Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features (1.1) • Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1.2) • Prophylaxis of migraine headaches (1.3) 1.1 Mania Divalproex sodium extended-release tablet is a valproate and is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. A manic episode is a distinct period of abnormally and persistently elev…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 090070

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 090070
Product	Strength	Form · route	Labeler	Product NDC
Divalproex Sodium	Divalproex sodium 500 mg/1	Tablet, Film coated, Extended releaseOral	Dr. Reddy's Laboratories Ltd	55111-534